Akari Therapeutics PLC Total Assets
Akari Therapeutics PLC total assets. Based on the latest financial reports, Akari Therapeutics PLC (AKTX) holds total assets worth $47.89 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AKTX stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Akari Therapeutics PLC (2010–2025)
Total assets of Akari Therapeutics PLC from 2010 to 2025. This chart illustrates how Akari Therapeutics PLC's total assets have evolved over time, based on quarterly financial data. See AKTX stock price and chart for real-time trading data and today's change.
Akari Therapeutics PLC - Asset Composition Analysis
Akari Therapeutics PLC Total Assets Breakdown (December 2025)
Akari Therapeutics PLC total assets breakdown as of December 2025. Akari Therapeutics PLC's total assets of $47.89 Million consist of 11.4% current assets and 88.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $34.00 Million | 71.0% |
| Goodwill | $8.43 Million | 17.6% |
Asset Composition Trend (2010–2025)
This chart illustrates how Akari Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Akari Therapeutics PLC to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akari Therapeutics PLC's current assets represent 11.4% of total assets in 2025, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2025, up from 0.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 87.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 71.0% of total assets.
Akari Therapeutics PLC Competitors by Total Assets
Key competitors of Akari Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Akari Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.44 | 0.15 | 2.00 |
| Quick Ratio | 0.44 | 0.15 | 2.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.89 Million | $-16.96 Million | $3.91 Million |
Akari Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Akari Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.26 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -5.3% |
| Total Assets | $47.89 Million |
| Market Capitalization | $7.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Akari Therapeutics PLC's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Akari Therapeutics PLC's assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Akari Therapeutics PLC (2010–2025)
The table below shows the annual total assets of Akari Therapeutics PLC from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $47.89 Million | -5.28% |
| 2024-12-31 | $50.56 Million | +1061.01% |
| 2023-12-31 | $4.36 Million | -68.52% |
| 2022-12-31 | $13.83 Million | +18.75% |
| 2021-12-31 | $11.65 Million | -20.25% |
| 2020-12-31 | $14.60 Million | +41.70% |
| 2019-12-31 | $10.31 Million | -37.35% |
| 2018-12-31 | $16.45 Million | -43.37% |
| 2017-12-31 | $29.05 Million | -36.67% |
| 2016-12-31 | $45.87 Million | -34.37% |
| 2015-12-31 | $69.89 Million | +978.60% |
| 2014-12-31 | $6.48 Million | -17.26% |
| 2013-12-31 | $7.83 Million | +599.29% |
| 2012-12-31 | $1.12 Million | +4048.15% |
| 2011-12-31 | $27.00K | -21.55% |
| 2010-12-31 | $34.42K | -- |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more